Royalty Pharma (RPRX)
(Real Time Quote from BATS)
$26.62 USD
-0.15 (-0.56%)
Updated Jul 15, 2024 10:46 AM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RPRX 26.62 -0.15(-0.56%)
Will RPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPRX
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
RPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for RPRX
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
7 Biotech Stocks to Buy on the Dip: June 2024
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Dividend Champion, Contender, And Challenger Highlights: Week Of June 9
Buy Rating Affirmed for Royalty Pharma Amidst Positive Earnings Forecast and Strategic Growth Deals